Bank of American: Lilly’s tirzepatide could be the first $100 billion drug

Bank of American: Lilly’s tirzepatide could be the first $100 billion drug

Bank of America analysts on Friday told investors that Eli Lilly & Co. Inc.’s (LLY) diabetes treatment and possible weight-management drug could be a $100 billion medication. The drug, tirzepatide, received Food and Drug Administration approval as a treatment for Type 2 diabetes earlier this year. It has also shown in clinical trials that it can help people lose up to 20% of their body weight.